IPHA News and Press, Innate Pharma S.A. From 01/04/24

2024-01-04 08:15:14 ET Minim  ( MINM ) +145% . Omega Therapeutics  ( OMGA ) +109% signs research deals on cardiometabolic diseases. Jeffs Brands  ( JFBR ) +41% . ATIF Holdings  ( ATIF ) +20% . Arena Group Holdings ( ...

2024-01-04 04:25:35 ET More on Innate Pharma: Innate Pharma jumps 15% on licensing natural killer cell engager with Sanofi Seeking Alpha’s Quant Rating on Innate Pharma For further details see: FDA lifts partial clinical hold on Innate Pharma's lacutamab c...

FDA lifts partial clinical hold on lacutamab clinical program Fatal case related to disease progression and unrelated to the treatment Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ...

Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and ...

2023-12-19 05:30:19 ET Stock futures were little changed on Tuesday after the major averages extended gains in the last session, as Fed officials attempt to rein in bets for earlier and deeper-than-expected rate cuts next year. Here are some of Tuesday's biggest stock movers: B...

2023-12-19 05:14:25 ET More on Innate Pharma, Sanofi Sanofi: A Shift In The Story EU regulators issue positive opinion on Sanofi sleeping sickness drug Biden administration secures 230K more RSV injections for infants For further details see: Innate Pharm...

Sanofi to exercise one option to license a new ANKET ® program from Innate; After a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization of the program Innate to receive €15m as option exercise payment ...

Current CEO Mondher Mahjoubi to leave Innate Pharma to pursue an opportunity at a large pharmaceutical company Current Chairman of the Supervisory Board, former CEO and company co-founder Hervé Brailly appointed interim CEO Irina Staatz-Granzer, current Vice-Chairwoman of Sup...

2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...

SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in patients with R/R A...